TribLIVE

| USWorld


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

'Reverse vaccine' for diabetes passes test

Daily Photo Galleries

By The Los Angeles Times
Saturday, June 29, 2013, 6:57 p.m.
 

LOS ANGELES — A “reverse vaccine” that allows people with Type 1 diabetes to produce their own insulin has passed its first test with human subjects, according to a new study. The success points to a potential strategy for treating those in the early stages of the disease, experts said.

The therapy is designed to protect cells in the pancreas that make insulin, a hormone the body needs to convert sugars and starches into energy. In people with Type 1 diabetes, the immune system goes haywire and attacks those crucial insulin-producing cells for reasons that medical researchers don't understand.

Researchers dubbed the treatment a reverse vaccine because it suppresses the immune system, instead of stimulating it. As hoped, the experimental vaccine reduced the number of immune system “killer” cells that went on the attack.

“We're trying to turn off one specific immune response,” said Dr. Lawrence Steinman, an immunologist at Stanford University and senior author of the study published Wednesday in Science Translational Medicine.

About 1.25 million Americans have Type 1 diabetes.

 

 
 


Show commenting policy

Most-Read Nation

  1. CIA admits Senate was spied on
  2. FDA will regulate labs’ ‘high-risk’ test devices
  3. House GOP balks on young immigrants bill
  4. Congress considers dangers of driving high
  5. CEO shot, wounded in Chicago, apparently by demoted executive
  6. Credit-card-stealing virus ‘Backoff’ virtually undetectable, Homeland Security warns
  7. Museum sleepover for adults sells out
  8. Stoned volunteers test drug, alcohol effect on driving
  9. Annapolis Marine capain could be 1st to perform as part of Blue Angels team
  10. Law enforcement, intelligence agencies want to ‘like’ you on social media
  11. Data on impact of Colo. gun law, background checks questioned
Subscribe today! Click here for our subscription offers.